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ABSTRACT PAGE
The neuropeptides orexin A and B (also known as  hypocretin 1 and 2) have been 
implicated in the regulation of feeding behavior, emotional arousal, and sleeping and 
waking behaviors. Previous research has indicated that orexin neurons projecting from 
the hypothalamus excite basal forebrain cholinergic neurons, resulting in increased 
awakefulness (Eggermann et al., 2001). The basal forebrain cholinergic system has 
been implicated in the regulation of attention (McGaughy et al., 1996). Collectively, these 
results suggest that orexins might play a role in attentional processing. The current 
studies assessed  the effects of systemic and intrabasalis administration of an orexin-1 
receptor anagonist, SB-334867 on attentional performance. Rats were trained on an 
attention task that required discrimination between visual signals (500 ms, 100 ms, and 
25 ms) and non-signals. In Experiment 1, the rats were each given three injections: a 
vehicle solution and two levels of SB-334867, 1.0 mg/kg and 5.0 mg/kg, counterbalanced 
across subjects. The results revealed an interaction for signal duration and dose. Visual 
detection at the 500 ms signal duration was impaired at the highest dose; in addition, 
performance at the 25 ms signal duration improved at the highest dose. In Experiment 2, 
rats were given four intrabasalis infusions: a vehicle solution and three doses of SB- 
334867, 0.15 pG/side, 0.33 pG/side, and 0.6 pG/side. No significant effects were found 
for dose. The data suggest that orexin A does play a role in regulating attention, though 
the link might be more complicated than previously thought.
TABLE OF CONTENTS
Page
Acknowledgements iv
Introduction 1
Basal Forebrain Corticopetal Cholinergic Neurons and 2
Attention in the Rat
Neuroanatomy of the Orexinergic System 5
Basal Forebrain Cholinergic Neurons and Orexins 9
The Current Experiments 10
Experiment 1
Methods 13
Results 17
Discussion 18
Experiment 2
Methods 21
Results 24
Discussion 25
General Discussion 27
References 30
Figure Captions 41
Figures 42
Vita 49
iii
Acknowledgements 
I would like to thank my advisor, Dr. Joshua Burk, for his guidance and 
patience throughout this process. In addition, I would like to thank Dr. Pamela 
Hunt and Dr. Jennifer Stevens for their time and helpful comments.
I would also like to thank Andrea Robinson, David Mangini, Puja Parekh, 
Will Bleser, Jon Weeks, Fuad Bohsali, Usmaan Bashir, Aileen Kim, Bethany 
Wilson, and Sarah Baum for their help with training the rats and lab upkeep.
As humans, we have a basic idea of what attention is and can report when 
it is being used. However, understanding the specific functions and processes of 
attention is more difficult. It is only relatively recently that scientific innovations 
have allowed scientists to map out some of the specific mechanisms of attention, 
as well as what brain regions make up the attentional system.
Classic attention research described attention as a process similar to 
decision-making (Broadbent & Gregory, 1963). Two models of attention were 
developed by researchers during this time: the early-selection model and the late- 
selection model (Broadbent & Gregory, 1963; Deutsch & Deutsch, 1963). Early- 
selection theory hypothesizes that selective attention places more emphasis on the 
selected stimulus, not by blocking out the unattended stimulus, but by reducing its 
intensity. This process takes place before the brain analyzes the content of the 
stimulus. Late-selection models hypothesize that the brain analyzes the content of
i
both stimuli but filters out irrelevant information. Thus, unattended stimuli never 
reach a conscious level of cognition.
Attention has been compared to shining a spotlight on the object which is 
being scrutinized (Cavanaugh, 2004). Only the object within the spotlight has 
been selected for higher processing, and objects outside of the spotlight are not 
further processed. Multiple spotlights, or areas of selection, can be functioning at 
once. By having these specific areas o f selection, the brain can filter out 
unimportant stimuli and send the more important information on for deeper 
processing. The attentional system displays limited capacity and acuity during 
selection tasks (Cavanaugh, 2004; Carr, 2004). One's ability to focus on multiple
2objects is limited, and the detail with which one can describe the object decreases 
as the load on the attentional system increases. Increased numbers of distractors 
can inhibit one's ability to focus efficiently on the selected object, compromising 
deeper processing.
The neuroanatomy of attention was first explored using electrode 
recordings in the superior colliculus during visual attention shifts in the macaque 
monkey (Wurtz & Goldberg, 1972). The first imaging studies offered more 
insight into the neural systems that underlie attentional processing, including the 
posterior parietal lobe and the anterior cingulate, both of which were found to be 
important for target detection in attention tasks (Posner & Petersen, 1990).
Since then, numerous other neural systems have been implicated in the 
regulation of attentional processing. A growing body of literature has implicated 
the cholinergic system as a key neurotransmitter within the attentional system. 
Specifically, cholinergic projections from the basal forebrain, in particular the 
nucleus basalis of Meynert, to the neocortex are implicated in attention.
Basal Forebrain Corticopetal Cholinergic Neurons and Attention in the Rat
Various tasks have been designed to measure attentional performance in 
rats. Researchers often use a five-choice serial task, which is specifically 
designed to tax attentional demands (Robbins, 2002). In this task, rats are required 
to monitor five locations for a 0.5 s visual signal presentation. A nose poke into 
an aperture underneath the signal presentation location (as measured by infrared 
photobeams) is scored as a correct response and results in a food reinforcement.
3An incorrect nose poke or no response results in a five second time out. This task 
tests the ability of the rat to maintain a level of spatial attention over 30 minutes.
Excitotoxic lesions to the basal forebrain result in reduced choice accuracy 
on this task, perhaps due to the removal of cholinergic input to the neocortex 
(Robbins, Everitt, Marston, Wilkinson, Jones, & Page, 1989). However, due to 
the nonspecificity of excitotoxic lesions, the learning impairments found in the 
five-choice serial reaction time task were not necessarily a result of the loss of 
cholinergic neurons. GABAergic and glutamatergic neurons are much more 
numerous within the basal forebrain than cholinergic neurons (Zaborsky, 
Gaykema, Swanson, & Cullinan, 1997). Since excitotoxic lesions completely 
destroy neurons within the target area and fibers o f passage, it is reasonable to 
speculate that it is the loss of another neuronal system, or the cumulative loss of 
the neurons within the basal forebrain, that decrease task performance (Everitt & 
Robbins, 1997).
Immunotoxins have allowed more targeted lesions of specific 
neurotransmitter systems. Specifically, researchers developed the cholinotoxin 
192 IgG-saporin, which selectively targets the p75 nerve growth factor receptors 
(Waite, Chen, Wardlow, Wiley, Lappi, & Thai, 1995). This nerve growth factor is 
expressed by cortically-projecting cholinergic neurons within the basal forebrain 
and some Purkinje cells within the cerebellum. Thus, this cholinotoxin 
selectively destroys neurons expressing p75 and leaves all other neurons intact. 
This allows for 192 IgG-saporin to be infused into cortical regions, such as the 
preffontal cortex (PFC), and only destroy cholinergic neurons within the basal
forebrain, which receives projections from the PFC. These immunotoxic lesions 
reduce levels of choline acetyltransferase by up to 90% with increasing doses 
(Holley, Wiley, Lappi, & Sarter, 1994; Waite et al., 1995). On a behavioral level, 
extensive intrabasalis lesions caused by 192 IgG-saporin resulted in decreased 
choice accuracy and an increase in omissions on a five-choice serial reaction time 
task (McGaughy, Dailey, Morrison, Everitt & Robbins, 2002).
In addition, 192 IgG-saporin has been shown to cause behavioral deficits 
in other tasks designed to tax attentional demands (Bushnell, Oshiro, & Padnos, 
1997; McGaughy & Sarter, 1998; Arnold, Burk, Hodgsom, Sarter, & Bruno, 
2002). Intrabasalis infusions of 192 IgG-saporin decreased signal detection on a 
visual discrimination task designed to have high attentional demands (McGaughy, 
Kaiser, & Sarter, 1996). This task is comprised of signal and non-signal trials. 
The signal trials are comprised of three signal durations, 500 ms, 100 ms, and 25 
ms. Rats are trained to press one lever in response to a signal presentation, and 
trained to press another lever in response to a non-signal or “blank” trial. 
Compared to the five-choice serial task, the visual discrimination task minimized 
the spatial and locomotor aspects of the task, while still being a valid measure of 
attentional performance (McGaughy & Sarter, 1995). In addition, the task is very 
sensitive to cholinergic manipulations. Rats that received 192 IgG-saporin lesions 
displayed significantly impaired visual detection of all signal durations. However, 
the percentage of correct lever responses to non-signal trials was not affected, 
indicating that the rats were still able to perform within the rules of the task.
5Neuroanatomy o f  the Orexinergic System
In the late 1990’s, two groups of researchers independently discovered a 
population of neuropeptides later known as orexin A and B (hypocretin 1 and 2), 
(Sakurai, Amemiya, Ishii, Matsuzaki, Chemelli, Tanaka, Williams, Richardson, 
Kozlowski, Wilson, Arch, Buckingham, Haynes, Carr, Annan, McNulty, Liu, 
Terrett, Elshourbagy, Bergsma, & Yanagisawa, 1998; de Lecea, Kilduff, Peyron, 
Gao, Foye, Danielson, Fukuhara, Battenberg, Gautvik, Bartlett, Frankel, van den 
Pol, Bloom, Gautvik, Sutcliffe, 1998). Orexin A and B are produced in the lateral 
hypothalamus and medially contiguous perifomical area (Sakurai, 2007; Mignot, 
Taheri, & Nishino, 2002). The orexin system projects to numerous brain regions 
including the locus coeruleus (LC), the preoptic area, paraventricular nucleus of 
the thalamus, basal forebrain, and spinal cord (Sakurai, 2007; Chemelli, Willie, 
Sinton, Elmquist, Scammell, Lee, Richardson, Williams, Xiong, Kisanuki, Fitch, 
Nakazato, Hammer, Saper, & Yanagisawa, 1999). Orexin A and B bind 
differentially to the two subtypes of orexin receptors, Orexin-1 and Orexin-2 
(Sakurai et al., 1998). Orexin A binds to Orexin-1 receptors with high affinity, 
while Orexin B binds with 100- to 1000-fold lower affinity. The orexin-2 receptor 
has a high affinity for both peptides.
The hypothalamus is important for regulating metabolic functions, as well 
as hunger, thirst, and circadian rhythms (Sakurai, 2007). Orexins are 
neuroexcitatory in nature, in that they increase axonal activity, specifically within 
the hypothalamus (de Lecea et al, 1998). They have been implicated in the
6regulation of energy homeostasis, hormone secretion, and feeding behaviors. In 
addition, orexins seem to play an important role in the maintenance of waking and 
sleeping patterns, as well as arousal states.
Orexin neurons have been implicated in autonomic homeostasis and 
hormone secretion. Orexins project to brain areas thought to be important for the 
regulation of heart rate and blood pressure, including the ventrolateral medulla 
and the locus coeruleus (Dampney, 1994). Orexins also might play a role in the 
regulation of body temperature, as they project to the raphe magnus and 
subcoeruleus (Werner & Bienek, 1990). Lesions o f the rostral raphe nuclei have 
been shown to cause a loss of thermoreactiveness within preoptic neurons. In 
addition, the location of orexinergic projections also supplies evidence that these 
neuropeptides are important in hormone secretion. Orexin neurons project to the 
arcuate nucleus, an area that houses numerous populations of hormone-secreting 
neurons, including gonadatropin-releasing hormone (Iqbal, Pompolo, Sakurai, & 
Clarke, 2001). Orexin A has been shown to decrease concentrations of growth 
hormone and prolactin, while Orexin B seems to have a direct effect on the 
function of the pituitary, adrenal, and pineal glands (Mikkelsen et al., 2001; 
Randeva, Karteris, Grammatopoulos, & Hillhouse, 2001; Samson & Taylor,
2001).
When first discovered, one of the primary functions of orexins was 
thought to be related to feeding behavior (Sakurai et al., 1998). Orexin neurons 
express leptin receptors, a peptide hormone encoded on the obese gene that 
suppresses appetite via action within the hypothalamus (Hakansson, de Lecea,
7Sutcliffe, Yanagisawa, & Meister, 1999; Horvath, Diano, & Van den Pol, 1999). 
Leptin knockout mice (ob/ob) also have decreased levels of the orexin precursor 
preprohypocretin mRNA (Yamamoto et al., 1999). In addition, periods of fasting 
increase orexin peptides levels within the hypothalamus (Sakurai et al., 1998; 
Mondal, Nakazato, Date, Murakami, Yanagisawa, & Matsukura, 1999).
Orexin’s effects on feeding have also been seen through behavioral 
studies. Short-term food consumption in rats has been found to be increased 
following intracerebroventricular administration of both orexin A and B (Sakurai 
et al., 1998). Similarly, orexin B increases food consumption in sheep (Sartin et 
al., 2001). Feeding behavior can also be increased following the intracranial 
administration of orexin A to various brain regions involved in feeding, including 
the lateral hypothalamus, perifomical area, and the dorsomedial hypothalamic 
nucleus. However, many researchers believe that orexin’s role in feeding is not as 
important as was first believed. Increases in feeding behavior could be a 
byproduct of orexin’s role in the sleep-wake cycle (Yamanaka, Sakurai, 
Katsumoto, Yanagisawa, & Goto, 1999; Fujiki, Yoshida, Ripley, Honda, Mignot, 
& Nishino, 2001). Orexins seem to promote wakefulness, which could in turn 
cause greater food intake.
Pathology of orexin neurons has been implicated in the sleep disorder 
narcolepsy with cataplexy. Narcolepsy is a rare neurological disorder 
characterized by excessive daytime sleepiness, sleep paralysis, hypnogogic 
hallucinations, and in some cases, cataplexy (NINDS, 2008). Orexin’s role in the 
sleep-wake cycle was first discovered through genetic mapping projects
8concerning the defective canine narcolepsy gene (Lin et al., 1999). The absence 
of orexins within the cerebrospinal fluid is a characteristic of narcolepsy (Nishino, 
Ripley, Overeem, Lammers, & Mignot, 2000; Ripley et al., 2001). Ripley and 
colleagues found that 37 out of 42 narcoleptics studied did not have detectable 
levels of orexins within their cerebrospinal fluid.
Orexin neurons within the lateral and perifomical hypothalamus receive 
projections from the superchiasmatic nucleus (SCN), which generates the 
circadian rhythm (Abrahamson, Leak, & Moore, 2001). Orexin levels within the 
brain fluctuate throughout the circadian rhythm, becoming more active during 
wakefulness. Sleep deprivation has been shown to increase orexin levels even 
further, suggesting that one of the primary functions of orexin is to promote 
wakefulness (Yoshida et al., 2001).
Activation of monoamine neurons in the LC, dorsal raphe (DR), and 
tuberomamillary nucleus (TMN) are critical for maintaining wakefulness, and are 
referred to as REM-off cells. These neurons are most active during wakefulness, 
less active during non-REM sleep, and are completely inactive during REM sleep 
(Saper, Chou, & Scammell, 2001; Mileykovskiy, Kiyashchenko, & Siegel, 2005). 
Administration of orexin A and B increases the activity of histaminergic neurons 
within the TMN, and orexin A has an excitatory effect on noradrenergic neurons 
within the LC and seratonergic neurons in the DR (Hagan et al., 1999). The 
excitation of these monoamines prolongs their activity, which decreases REM 
sleep and increases arousal.
9Behaviorally, intracerebroventricular injections of orexin A have been 
found to increase arousal as measured by increased locomotion in an X-maze and 
increased startle responses (Hagan et al., 1999). In addition, support for orexin’s 
role in cognitive processing has been shown in sleep-deprived rhesus monkeys 
(Deadwyler, Porrino, Siegel & Hampson, 2007). Systemic and intranasalis 
administration of orexin A significantly improved performance on a delayed 
match-to-sample task following 30 to 36 hours of sleep deprivation. No 
improvements were seen after drug administration following normal sleep.
Basal Forebrain Cholinergic Neurons and Orexins
Neuroanatomical research has found numerous axonal hypothalamic 
projections onto cholinergic neurons in the basal forebrain (Cullinan & Zaborsky, 
1991). Fadel, Pasumarthi, and Reznikov (2005) found orexin-immunoreactive 
fibers positioned closely to cholinergic neurons, suggesting that orexin projections 
from the hypothalamus map directly onto cholinergic neurons within the basal 
forebrain. Infusions of orexin A into the basal forebrain result in increased 
wakefulness in rats (Espana, Baldo, Kelley, & Berridge, 2001). Electrodes 
monitored brain wave patterns during sleeping and waking cycles, showing that 
total time awake increased, and total time spent in slow wave sleep and rapid eye 
movement sleep decreased. More specifically, Eggermann and colleagues (2001) 
found that orexins excite cholinergic neurons in the basal forebrain, resulting in 
increased cortical activation and awakefulness.
Fadel and colleagues (2005) used microdialysis to assess the effect of 
orexin A on cholinergic release in the PFC. Levels of ACh in the PFC
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significantly increased after intra-basalis administration of orexin A. Infusions of 
orexin A directly into the PFC did not increase PFC ACh. These data suggest that 
intrabasalis infusions of orexin A can affect levels of ACh in brain areas 
important for various cognitive functions, including attention. Fadel and 
Frederick-Duus (2008) theorize that orexins modulate basal forebrain ACh in 
response to visual stimuli that are relevant to one’s physiological state, including 
hunger or thirst level. This would be especially relevant to the current study, in 
which appetitive motivation is being assessed using a visual discrimination task. 
The Current Experiments
The current experiments use a previously validated attention task. The task 
has been tested with various manipulations (McGaughy & Sarter, 1995), 
including background noise, high event rates, and event asynchrony. During this 
task, rats are required to visually discriminate between three signal durations and 
a nonsignal trial, and then respond by pressing the correct lever. The introduction 
of “background noise” (in the form of a flashing house light) resulted in impaired 
signal detection between signal and non-signal trials, indicating that flashing light 
distracted the rats from achieving optimal performance. In addition, the flashing 
houselight resulted in increased rate of poorer signal detection of the shortest 
signal duration during the last block of trials. This vigilance decrement could be a 
form of attentional fatigue. Rats often respond to the shortest signal duration as a 
non-signal trial, by pressing the incorrect lever. This signal length could require 
more attentional resources to detect, thus being affected by a vigilance decrement 
before the other signal durations, especially in the presence of a distraction. High
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event rates, or a higher number of trials per minute (defined as having 9 ± 3 s in 
between trials), also augmented this vigilance decrement. In addition, event 
asynchrony was used to test the rat’s ability to time trial onset. To achieve this, 
the inter-trial interval (ITI) was varied across trials (12 ± 6 s). Highly varied ITI 
had no effect on attentional performance, as it did not affect signal detection or 
the number of trials omitted (not responded to). Thus, it is unlikely that the rats 
were timing trial onset. McGaughy and Sarter also used animal age as a variable 
to test task validity. Normal aging results in attentional deficits (Verhaeghen & 
Cerella, 2002). Twenty month old rats were less able to discriminate between the 
shortest signal duration and the nonsignal trials as compared to young rats, as 
displayed by an increased number of incorrect lever responses following the 
shortest signal duration. However, no deficits were found during the nonsignal 
trials, indicating that the rats knew the rules of the task. The previous data 
support that the current task is a valid measure of attention in the rat.
To examine differences in cortical ACh release during and after task 
performance, Arnold and colleagues (2002) compared two control procedures that 
did not explicitly tax attention to the current task. First, a basic operant control 
task using a fixed ratio schedule of 9, but in which only 60% of these intervals 
were rewarded; this task was designed to explore the effects of simple operant 
responding. The second task was designed to assess the effects of lever extension 
as a prompt for responding. This task mirrored the first control procedure, except 
that only one lever was extended into the chamber. ACh levels within the cortex 
were measured using microdialysis during and after task performance. The two
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control procedures resulted in dramatically smaller increases in cortical ACh 
efflux (about 50%) compared to increases following the current task (about 
140%). These data support that the current task requires high attention demands 
which in turn elevate cortical ACh levels.
Specifically important for the current experiments, visual signal detection 
in this task has been shown to be sensitive to various basal forebrain cholinergic 
manipulations, including cortical cholinergic deafferentation produced by 
intrabasalis infusions of 192 IgG-saporin (McGaughy et al., 1996). Moreover, 
signal detection in this task is also sensitive to other manipulations of basal 
forebrain neurons that depress cortical ACh release, including intrabasalis 
infusions of an NMDA receptor antagonist (Turchi & Sarter, 2001) or a 
benzodiazepine receptor agonist (Holley, Turchi, Apple, & Sarter, 1995; 
McGaughy & Sarter, 1995).
The current experiments assessed the effects of systemic and intrabasalis 
administration of the orexin-1 receptor antagonist SB-334867. While orexin A 
has been implicated in increased wakefulness and cognitive functioning, an 
orexin-1 receptor antagonist was used in this study due to the ceiling effect 
observed in the attentional task used. Rats often perform with over 90% accuracy 
on the longer signal durations, making attentional enhancements difficult to 
observe. Experiment 1 investigates the effects of systemic injections of SB- 
334867. Administration of the orexin-1 receptor antagonist was expected to 
decrease ACh release within the cortex, resulting in impaired visual signal 
detection. Experiment 2 investigates the effects of localized infusions of SB-
13
334867 into the basal forebrain. Infusions of the orexin-1 receptor antagonist were 
expected to result in impaired signal detection, similar to the impaired signal 
detection expected in Experiment 1.
Experiment 1
Methods
Subjects. Subjects were 16 male Long-Evans rats, approximately two 
months old at the beginning of the experiment (Charles River Laboratories, Inc., 
Wilmington, MA). All animals were experimentally naive. The rats were housed 
individually in a temperature- and humidity-controlled environment with a 14/10 
hour light/dark cycle. All behavioral testing took place between 0900 and 1200, 
five days per week. Animals were water restricted for the duration of the 
behavioral testing, only receiving water during the task and for 30 minutes after 
the testing session. The rats were allowed free access to water on days when no 
behavioral testing occurred. Food was available ad libitum for the duration of 
experiment. The experimental protocol was approved by the Institutional Animal 
Care and Use Committee at the College of William and Mary, and all animals 
were handled according to Guidelines for the Care and Use of Laboratory 
Animals as set forth by the National Institutes of Health (National Research 
Council, 1996).
Apparatus. The rats were trained in 12 chambers each housed within a 
sound-attenuating box. One side of the chamber contained two retractable levers, 
a water port with an automated water delivery dipper (0.01 ml) located between 
the two levers, and three panel lights. One panel light was positioned directly
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over each retractable lever, and one panel light was centrally located above the 
water port. Only the centrally located panel light was used for this experiment. A 
house light was located on the other side of the chamber. The house light 
remained illuminated during all behavioral training and testing. Luminance levels 
of the house and panel lights have been previously described (Burk, 2004). 
Behavioral training and testing programs were administered by a personal 
computer using the Med-PC version IV software.
Behavioral training procedures. The house light was illuminated during 
all training procedures and the test task. During the first stage of training, the 
retractable levers were extended into the chamber at all times. The water dipper 
was raised after each lever press. To discourage side bias, five consecutive 
presses on a lever resulted in the discontinuation of water access until the other 
lever was pressed. Rats were required to meet a criterion of 120 lever presses per 
session for three sessions in order to move on to the next training stage. During 
the second training stage, the rats were trained to discriminate between signals (1 
s illumination of the panel light) and non-signals (no illumination of the light). 
After a signal or non-signal was presented, the retractable levers were extended 
into the chamber. Half o f the rats were trained to press the left lever after a signal 
presentation, which would be scored as correct, or a hit, and water access would 
be provided. If the rat pressed the right lever after a signal trial, this was 
considered to be a miss. Following a non-signal presentation, a press on the right 
lever was considered to be a correct rejection and water access was provided. A 
press to the left lever was considered to be a false alarm. The rules of the task
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were reversed for half of the rats, meaning that the right lever was the correct 
response following signal presentation and the left lever was the correct response 
following a non-signal. Incorrect choices were followed by a correction trial that 
was identical to the previous trial; three incorrect choices in a row resulted in a 
forced choice trial in which only the correct lever was extended for 90 s. During 
the forced choice trial, the panel light remained illuminated for the duration of the 
lever extension. For all trials, if no lever press was made within three seconds 
after lever extension, the trial was scored as an omission. The inter-trial interval 
(ITI) for this stage of training was 12±3 s, to reduce anticipation of the beginning 
of the next trial. Criterion for completion of this stage of training was set at 70% 
hits and 70% correct rejections for three consecutive sessions.
During the final version of the task, three signal durations were used: 500 
ms, 100 ms, and 25 ms. The presentation of these signal durations was randomly 
varied. There were a total of 162 trials each session (81 signal, 81 non-signal). In 
addition, the ITI was reduced to 9±3 s. No correction trials or forced choice trials 
were used during the final task. The animals were trained on this task until the 
criterion of 70% hits on the 500 ms signal and 70% correct rejections for three 
consecutive sessions was met. Once criterion was reached, drug administration 
for the present experiment began.
Procedures for SB-334867 administration. The orexin-1 receptor 
antagonist SB-334867 (Tocris Bioscience, Ellisville, MO) was suspended in a 
vehicle solution of 1.0 mL saline, 200 mg Hydroxy-beta-cyclodextran, and 125 
pL 100% DMSO. After the addition of SB-334867, the solution was vortexed for
16
30 minutes prior to injection. Fresh vehicle solution was prepared the day of 
injection, with excess solution being discarded after use.
The rats received three i.p. injections: vehicle solution, 1.0 mg/kg SB- 
334867, and 5.0 mg/kg SB-334867 in a counterbalanced order. All injections 
were administered immediately prior to the beginning of each testing session.
The testing program had a 10-min delay included at the beginning of each testing 
session to allow time for the drug to cross the blood-brain barrier. Satiety studies 
have shown that significant effects of SB-334867 begin 20 minutes after i.p. 
administration and peak after one hour (Rodgers, Halford, Nunes de Souza, Canto 
de Souza, Piper, Arch, Upton, Porter, Johns, & Blundell, 2001). At least two days 
of behavioral training took place between drug administrations in order to 
reestablish baseline task performance, which was defined as three consecutive 
days of 70% hits on the 500 ms signal and 70% correct rejections.
Behavioral measures and statistical analyses. The number of hits (H), 
misses (M), correct rejections (CR), false alarms (FA), and omissions were 
recorded for each testing session. Each session was divided into three blocks 
(trials 1-54, trials 55-108, and trials 109-162) to assess the effect of the drug 
within each session; sessions were also divided by signal duration (500 ms, 100 
ms, and 25 ms). The relative number of hits per block at each signal duration, as 
well as the overall session was calculated as (H/H+M), and the relative number of 
correct rejections per block and for the overall session was calculated as 
(CR/CR+FA). Omissions were analyzed separately from measures of response 
accuracy. The mean response latencies for hits, misses, correction rejections, and
17
false alarms were calculated and analyzed using as multi-factor ANOVA with the 
trial outcomes as factors.
The relative number of hits was analyzed using a repeated-measures 
analysis o f variances (ANOVA) with the factors of signal duration, block, and 
dose. The relative number of correct rejections was also analyzed using a 
repeated-measures ANOVA with the factors of block and dose.
Results
The data reported here are from the 13 rats that maintained stable 
performance levels in between drug administration sessions. This study assessed 
the effects of systemic administration of orexin antagonist SB-334867 on 
performance on an attention task. A repeated measures ANOVA on the relative 
number of hits for the three signal durations found a significant main effect for 
signal duration (F(2, 24) = 212.9, p  < .001). Rats exhibited signal duration- 
dependent accuracy, with the hit rate higher following longer signal durations 
(Figure 1). For hits, a significant interaction was found for signal duration and 
dose (F(4,48) = 3.06,p  < 0.05). Compared to vehicle administration, the hits 
following 5.0 mg/kg SB-334867 were lower on 500 ms signal trials (t( 12) = 2.36, 
p  < 0.05). The hit rate to the 25-ms signal was elevated following 1.0 mg/kg SB- 
334867 compared to vehicle administration (t(12) = 2.58,p  < 0.05; Figure 2). No 
other significant effects were found for the relative hits. A repeated-measures 
ANOVA for the relative number of correct rejections found no significant main 
effects for block or dose (Figure 3). No significant effects were found for lever 
press latency or omissions.
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Discussion
Experiment 1 investigated the effect of the orexin-1 receptor antagonist 
SB-334867 on performance on an attention task. Systemic administration of the 
orexin-1 antagonist resulted in decreased signal detection at the highest dose (5.0 
mg/kg SB-334867) for the longest signal duration (500 ms). In addition, signal 
detection of the shortest signal duration (25 ms) was improved at 1.0 mg/kg SB- 
334867 dose. A trend showing increased signal detection of the 25 ms signal 
flowing the highest dose was also found. No deficits were found for the non­
signal trials as the number of correct rejections did not change across dose. The 
lack of drug-induced or, in previous experiments, lesion-induced effects on 
detection of non-signals has been used as an indicator that the subjects displayed 
no lever bias and were continuing to respond based on the task rules (McGaughy 
et al., 1996). No severe motor or motivational deficits due to the effects of the 
drug were detected, as evidenced by the lack of change in response latencies or 
trial omissions.
The above factors are important to consider when interpreting the changes 
in signal detection found. The decrease in signal detection at the 500 ms signal 
duration indicates that the highest dose of SB-334867 may decrease cortical ACh 
release. McGaughy & Sarter (1998) found a similar pattern after moderate 
ablations of cortical cholinergic inputs in 192 IgG-saporin-lesioned rats; only the 
hit rate to the longest signal duration (also 500 ms) was impaired. Administration 
of SB-334867 might have resulted in a moderate impairment of the cholinergic
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system, resulting in the pattern of detection deficits at the longest signal duration 
reported here.
One unexpected result in the present experiment was that 1.0 mg/kg SB- 
334867 elevated detection of the 25 ms signal. This increase in signal detection is 
not necessarily indicative of attention enhancements. Signal detection remained 
stable at the 100 ms signal duration for all doses; if attentional enhancement took 
place, increased signal detection could be expected at the 100 ms signal duration 
as well. In addition, signal detection was decreased following the 500 ms signal. 
Thus, the reason for this improved signal detection remains speculative. The 
signal-driven and cognitive modulation hypotheses of signal detection offer 
potential explanations for the current results, specifically the improved detection 
at the 25 ms signal duration (Sarter, Hasselmo, Bruno, & Givens, 2005). 
According to this model, cortical acetylcholine release, functioning in response to 
signal properties and cognitive context, is involved in determining whether a 
particular event is responded to as a signal or non-signal. In the current study, 
rats appear to typically respond to the 25 ms signal as a non-signal during baseline 
task performance, resulting in a low number of hits at this signal duration. The 
average percentage of correct responses at the 25 ms signal following the vehicle 
dose was 21%, indicating on 79% of the trials, rats were responding to the 25 ms 
signal as if it was a non-signal. Administration of SB-334867 may have 
decreased cortical ACh release, altering this top-down process, changing the rat’s 
criterion for identifying events as signals. A “riskier” criterion may have led to 
the increase in hits following the 25 ms signal.
The PFC has been implicated in the regulation of top-down attentional 
processing via the cholinergic and glutamatergic systems (Nelson, Sarter, & 
Bruno, 2005). The corticopetal cholinergic system of the basal forebrain aids in 
sensory optimization that filters out interfering information such as distractors and 
background noise, and receives glutamatergic and cholinergic input originating 
from the PFC (Sarter, Givens, & Bruno, 2001). The orexin receptor antagonist 
SB-334867 could affect PFC outputs to the basal forebrain, resulting in the shift 
bias seen in the current data. The neurochemical basis for this shift in bias 
remains unsettled.
Another explanation of the elevated detection of the 25 ms signal at the 
1.0 mg/kg SB-334867 dose can be found in dopamine-related research. 
Amphetamine-induced dopamine release has been shown to increase the number 
of hits at the shortest signal duration (also 25 ms) by an average of 20% on the 
attention task used in the present study (Deller & Sarter, 1998), which is similar 
the results found in this study. No changes at the longer signal durations (500 ms 
and 50 ms) were found. Deller and Sarter (1998) suggested that behavioral 
sensitization caused by repeated exposure to amphetamines led to the increase in 
signal detection at the shortest duration. Orexin A within the ventral tegmental 
area has been implicated in having a critical role in behavioral sensitization after 
cocaine exposure (Borgland, Taha, Sarti, Fields, & Bonci, 2006). While this 
evidence suggests that a link between orexins and the dopamine system could 
account, at least in part, for the results found in the current study, amphetamine 
administration also led to an increase in false alarms, which was not observed in
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the current study. Thus, the cause of the increased hit rate at the 25 ms signal 
duration remains speculative.
Future research into the link between dopamine and orexins would be 
beneficial in explaining the results found in the present study. While orexins 
seem to regulate dopamine release within several brain regions, a clear cut pattern 
of effect has not been established. Infusions of an orexin antagonist into the 
ventral tegmental area during the attention task would assess the specific effects 
of the drug on the dopaminergic neurons in this region. Recent research has 
suggested that dopamine negatively modulates acetylcholine release in the basal 
forebrain via the PFC-nucleus accumbens pathway (Brooks, Sarter, & Bruno, 
2007). However, the interaction between dopamine and ACh, as well as the 
neural circuits involved, needs to be explored in more depth.
Experiment 2
One of the limitations of Experiment 1 was that i.p. injections were 
used, causing the drug spread throughout the brain and the periphery, making it 
difficult to know which neurotransmitter systems were affected and how this, in 
turn, affected task performance. To address this, as well as to explore 
acetylcholine’s role in Experiment 1 ’s results, Experiment 2 was designed to 
assess the effects of localized infusions of SB-334867 into the basal forebrain. 
Methods
Subjects. Subjects were 11 male Long-Evans rats, approximately two 
months old at the beginning of the experiment (Charles River Laboratories, Inc., 
Wilmington, MA). All animals were experimentally nai've. Animal housing and
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care procedures were identical to those described in Experiment 1. The 
experimental protocol was approved by the Institutional Animal Care and Use 
Committee at the College of William and Mary, and all animals were handled 
according to Guidelines for the Care and Use of Laboratory Animals as set forth 
by the National Institutes of Health (National Research Council, 1996).
Apparatus and behavioral training procedures. The experimental 
apparatus and training procedures used were identical to those described in 
Experiment 1. The animals were trained on this task until the criterion of 70% 
hits on the 500 ms signal and 70% correct rejections for three consecutive 
sessions was met.
Surgical procedures. After reaching baseline criterion in the attention 
task, animals received bilateral intrabasalis guide cannulae implantations. Prior to 
surgery, rats received 2.7 mg/ml acetaminophen diluted in water overnight. 
Animals were anesthetized using intraperitoneal (i.p.) injections of 90.0 mg/kg 
ketamine and 9.0 mg/kg xylazine. Animals were shaved using an electric razor, 
and placed in a stereotaxic device (Kopf Instruments, Tujunga, CA) with the 
incisor bar set 3.3mm below the interaural line (IA). An incision was made along 
the midline from anterior to posterior, exposing the skull. Holes were made over 
the target coordinates for guide cannulae implantation (AP: -1.3, ML: +/- 2.7 from 
bregma; DV: +3.5 from I A). Eight mm guide cannulae were used, with internal 
cannulae extending 1 mm beyond the guide cannulae. Three jeweler’s screws 
were also inserted into the skull. Dental cement was used to secure guide 
cannulae placement. Dummy cannulae were inserted to prevent clogging. Rats
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were given free access to food and water for one week after surgery, after which 
the rats were returned to water restriction and began to retrain on the task. Once 
the rats reached reestablished performance criterion, infusion procedures began.
Procedures for SB-334867 infusions. The vehicle solution and preparation 
procedures were identical to those described in Experiment 1. The rats received 
four drug doses: vehicle solution, 0.15 pg/pl, 0.3 pg/pl, and 0.6 pg/pl SB-334867, 
in a counterbalanced order. Infusions were given through an internal cannulae 
attached to a 1.0 pi Hamilton syringe via polyethylene tubing at a rate of 0.5 
pl/minute (0.5 pi per hemisphere). Due to technical difficulties, a subset of 
animals (N=7) received all infusion types at a rate of 1.0 pl/minute. All infusions 
were administered immediately prior to each testing session. At least two days of 
behavioral training took place between each infusion to reestablish baseline task 
performance.
Histological procedures. Rats were deeply anesthetized with 90.0 mg/kg 
ketamine and 9.0 mg/kg xylazine. Rats were then transcardially perfused with 
10% sucrose and 10% formalin at a pressure of 300mmHg using a Perfusion One 
instrument (myneurolab.com, St. Louis, MO). The brains were then removed and 
put into formalin for no more than 48 hours. The tissue was then put into a 30% 
sucrose solution in phosphate-buffered saline for at least three days. The tissue 
was then frozen and sectioned (40 pm) using a freezing microtome. Every 
section was saved and mounted. The tissue was then stained using cresyl violet. 
Slides were analyzed using an Olympus BX-51 Research microscope to assess 
cannulae placement.
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Behavioral measures and statistical analyses. The behavioral measures 
used in Experiment 2 were the same as those used in Experiment 1. As in 
Experiment 1, the relative number of hits, correct rejections, and omissions were 
analyzed using repeated-measures analysis of variances (ANOVA).
Results
Histological analyses. Analyses confirmed that cannulae were correctly 
placed in ten animals. Only these animals were included in the analyses. The tips 
of the guide cannulae were located approximately 1 mm above the target brain 
region. Internal cannulae extended 1 mm beyond the ends of the guide cannulae. 
Among the animals included in the statistical analyses, only minor variations in 
placement were observed.
Statistical analyses. This study assessed the effects of intrabasalis 
infusions of the orexin antagonist SB-334867 on attentional performance. One 
animal was discarded from behavioral data analysis due to incorrect cannulae 
placement. The data reported here are from the ten rats with cannulae located 
within the basal forebrain. A repeated-measures ANOVA on the relative number 
of hits for the three signal durations found a main effect for signal duration 
(F(2,18) = 113.73,/? < 0.001). Rats exhibited a signal duration-dependent 
accuracy, with the hit rate higher following longer signal durations. For hits, no 
significant main effects were found for dose or block (p = 0.84 andp  = 0.56) (see 
Figure 4).
In addition, no significant interactions were found. However, inspection 
of the means revealed some trends concerning the effects of drug administration
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on the hit rate, mainly during the third block of trials within a session. The 
relative number of hits following the 500 ms signal duration for the third block of 
trials following the 0.6 pi SB dose was slightly lower for the third block following 
vehicle administration (see Figure 5). However, exploratory /-tests comparing 
signal detection during the third block following vehicle and the 0.6 pG/side 
infusion did not find any significant effects.
A repeated measures ANOVA on the relative number of correct rejections 
found a significant main effect for block (F(2,18) = 7.26,/? < 0.01) (see Figure 6). 
Rats exhibited a higher correct rejection rate during the second block of trials as 
compared to the first and third blocks. No other significant main effects or 
interactions were found for correct rejections. Overall, no differences in 
performance on non-signal trials were found between dose levels (see Figure 7).
In addition, no significant effects were found for omissions.
Discussion
Experiment 2 investigated the specific action of orexins within the basal 
forebrain on attentional performance in rats. Intrabasalis infusions of the orexin-1 
receptor antagonist SB-334867 did not result in any significant dose-related 
results. Significant main effects for signal duration were found, in that rats 
performed better at the longer signal durations compared to the shorter signal 
durations. However, these effects were expected on this task and remained 
constant across dose. Signal detection at the 500 ms signal duration tended to be 
lower during the third block of trials following the 0.6 mg/pL dose, however this 
effect was not significant. It is possible that the highest dose of SB-334867 could
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have caused a vigilance decrement after prolonged attentional performance. 
Deficits in attention performance have been found in humans as a function of time 
(Paus, Zatorre, Hofle, Caramanos, Gotman, Petrides, & Evan, 1997). Participants 
showed decreased correct responses and increased reaction time during a 60 
minute auditory attention task. In addition, there was a decrease in cerebral blood 
flow to the substantia innominata, a region of the basal forebrain. More specific 
to the current attention task, high event rates and lower intensity signals have been 
shown to perpetuate a vigilance decrement on signal trials (McGaughy & Sarter, 
1995; Bushnell, 1999).
A significant main effect was found for block during non-signal trials.
Rats performed better during the second block of trials as compared to the first 
and third blocks. This pattern could be due in part to a “warm up” effect 
following the infusion procedure. This effect can be observed as the rats 
performing more poorly during the beginning of a testing session as compared to 
later trials. In addition, vigilance could deteriorate after prolonged task 
performance, resulting in the decreased rate of correct rejections during the third 
block o f trials, similar to the trend found during the third block following the 500 
ms signal duration after the highest dose.
General Discussion 
The first experiment was designed to assess the overall effects of the 
orexin-1 receptor antagonist SB-334867 on attentional performance via the use of 
systemic injections. However, it is unknown how much of the drug was absorbed 
in the periphery. The orexin-1 receptor antagonist affected many brain areas, not
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just regions specialized for attention. To address this problem, the second 
experiment was designed to investigate the effects of localized infusions of SB- 
334867 into the basal forebrain. These infusions did not produce the effects 
observed in Experiment 1. One suggestion would be to use higher doses of SB- 
334867. However, the doses used are within the range of those previously shown 
to increase wakefulness (Thakkar, Ramesh, Strecker, & McCarley, 2001). In 
addition, Fadel and colleagues (2005) showed increased cortical ACh efflux after 
0.1 pM infusions. Due to the trend found during the third block following the 500 
ms signal duration after the 0.6 pg infusion, increasing the time between the 
initial infusion and onset of behavioral training might uncover significant 
attentional deficits. However, it is not know if the trend observed is due simply to 
time after the initial drug infusion, if orexin’s actions within the basal forebrain 
interact with time-on-task, or simply due to the increasing number of trials. It is 
also possible that the changes in signal detection seen in Experiment 1 are due to 
SB-334867’s action in a brain area other than the basal forebrain or on a different 
neurotransmitter system, such as glutamate or GABA.
The PFC is important for attention processing, and receives cholinergic 
projections from the basal forebrain (Fadel et al., 2005). Intrabasalis infusions of 
orexin A have been shown to increase ACh efflux within the PFC. While no 
significant dose-related results were found in Experiment 2, a microdialysis study 
might be useful in monitoring the effect of the orexin-1 antagonist on cholinergic 
levels in the PFC during the task. Previous microdialysis research (Fadel et al, 
2005) found that infusions of orexin A increased ACh efflux within the cortex,
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suggesting that a similar pattern would be found during task performance on an 
ACh-dependent task. An orexin-1 receptor antagonist such as SB-334867 would 
block this efflux of ACh, perhaps keeping ACh at lower levels (perhaps similar to 
those seen during non-attenionally demanding tasks by Burk & Sarter, 2001).
The statistical power of the present experiments is also limited due to the 
small number of subjects used in both cases. In Experiment 1, a larger number of 
animals may have revealed a significant increase in signal detection following a 
25 ms signal at the highest dose of SB-334867. In Experiment 2, there was quite 
a bit of variability among subjects, specifically with the number of omissions at 
the higher doses of SB-334867. The standard error for overall omissions 
following the vehicle dose was 3.69 (calculated as SD/V(10), where SD is the 
standard deviation of the sample). The standard error for overall omissions 
following the 0.6 pG/side infusion was 13.77. There was also a high level of 
variability for hits across blocks in Experiment 2 as compared to the hits in 
Experiment 1. This variability could be a result of SB-334867 administration 
(though not found to be significant as a function of dose); it could also be 
obscuring any effects the drug might have had. A larger number of animals could 
result in more clear cut patterns within the data.
In summary, systemic injections of orexin-1 receptor antagonist SB- 
334867 did decrease performance on an attention task in the hypothesized 
manner. Detection of the 500 ms signal was lower following the highest dose (5.0 
mg/kg) of SB-334867 compared to vehicle administration. In addition, signal 
detection of the shortest signal duration (25 ms) was significantly improved at the
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1.0 mg/kg dose. No significant dose-dependent results were found following 
intrabasalis infusions of SB-334867. Thus, it is likely that orexin’s interaction 
with another neural system, such as the dopaminergic pathway in the PFC, 
contributed to the current results. The present data offer a starting point into 
understanding the relationship between orexins and the cholinergic system during 
an attention task.
30
References
Abrahamson, E. E., Leak, R. K. & Moore, R.Y. (2001). The suprachiasmatic
nucleus projects to posterior hypothalamic arousal systems. Neuroreport, 
12, 435^40.
Arnold, H.M., Burk, J.A., Hodgson, M., Sarter, M., & Bruno, J.P. (2002).
Differential cortical acetylcholine release in rats performing on a sustained 
attention task versus behavioral control tasks that do no explicitly tax 
attention. Neuroscience, 114, 451-460.
Borgland, S.L., Taha, S.A., Sarti, F., Fields, H.L., & Bonci, A. (2006). Orexin A 
in the VTA is critical for the induction of synaptic plasticity and 
behavioral sensitization to cocaine. Neuron, 49, 589-601.
Broadbent, D.E. & Gregory, M. (1963). Division o f attention and the decision 
theory of signal detection. Proceedings o f  the Royal Society o f  London. 
Series B, containing papers o f  a biological character, 158, 222-231.
Brooks, J.M., Sarter, M., & Bruno, J.P. (2007). D2-like receptors in nucleus
accumbens negatively modulate acetylcholine release in preffontal cortex. 
Neuropharmacology, 53, 455-463.
Burk, J. A. (2004). Introduction of a retention interval in a sustained attention task 
in rats: Effects of a visual distracter and increasing the inter-trial interval. 
Behavioural Processes, 67, 521-531.
Burk, J.A. & Sarter, M. (2001). Dissociation between the attentional functions 
mediated via basal forebrain cholinergic and GABAergic neurons. 
Neuroscience, 105, 899-909.
31
Bushnell, P.J. (1999). Detection of visual signals by rats: Effects of signal
intensity, event rate, and task type. Behavioural Processes, 46, 141-150.
Bushnell, P.J., Oshiro, W.M., & Padnos, B.K. (1997). Detection of visual signals 
by rats: Effects of chlordiazepoxide and cholinergic and adrenergic drugs 
on sustained attention. Psychopharmacology, 134, 230-241.
Carr, (2004). A multilevel approach to selective attention: Monitoring
environmental space, choosing stimuli for deep processing, and retrieving 
information from memory. In M.I. Posner (Eds.), Cognitive neuroscience 
o f  attention (pp. 56-70). New York: The Guilford Press.
Cavanaugh, P. (2004). Attention routines and the architecture of selection. In M.I. 
Posner (Eds.), Cognitive neuroscience o f  attention (pp. 13-28). New York: 
The Guilford Press.
Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammell, T., Lee, C., 
Richardson, J.A., Williams, S.C., Xiong, Y., Kisanuki, Y., Fitch, T.E., 
Nakazato, M., Hammer, R.E., Saper, C.B., & Yanagisawa, M. (1999). 
Narcolepsy in orexin knockout mice: Molecular genetics of sleep 
regulation. Cell, 98, 437-451.
Cullinan, W.E. & Zaborsky, L. (1991). Organization of ascending hypothalamic 
projections to the rostral forebrain with special reference to the 
innervation of cholinergic projection neurons. Journal o f  Comparative 
Neurology, 306, 631-667.
Dampney, R.A.L. (1994). Functional organization of central pathways regulating 
the cardiovascular system. Physiology Review, 74, 323-364.
Deadwyler, S.A., Porrino, L., Siegel, J.M., & Hampson, R.E. (2007). Systemic 
and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep 
deprivation on cognitive performance in nonhuman primates. The Journal 
o f  Neuroscience, 27, 14239-14247.
de Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., 
Fukuhara, C., Battenberg, E.L., Gautvik, V.T., Bartlett, F.S., Frankel, 
W.N., van den Pol, A.N., Bloom, F.E., Gautvik, K.M., & Sutcliffe, J.G. 
(1998). The hypocretins: hypothalamus-specific peptides with 
neuroexcitatory activity. Proceedings from the National Academy o f  
Sciences, USA, 95, 322-327.
Deller, T. & Sarter, M. (1998). Effects of repeated administration of amphetamine 
on behavioral vigilance: Evidence for “sensitized” attention impairments. 
Psychopharmacology, 137, 4410-414.
Deutsch, J.A. & Deutsch, D. (1963). Attention: Some theoretical considerations. 
Psychological Review, 70, 80-90.
Eggermann, E., Serafin, M., Bayer, L., Machard, D., Saint-Mleux, B., Jones, B.E., 
& Muhlethaler, M. (2001). Orexins/hypocretins excite basal forebrain 
cholinergic neurones. Neuroscience, 108, 177-181.
Espana, R.A., Baldo, B.A., Kelley, A.E., & Berridge, C.W. (2001). Wake-
promoting and sleep-suppressing actions of hypocretin (orexin): Basal 
forebrain sites of action. Neuroscience, 106, 699-715.
Everitt, B.J. & Robbins, J.L. (1997). Central cholinergic systems and cognition. 
Annual Review o f  Psychology, 48, 649-684.
33
Fadel, J. & Frederick-Duus, D. (2008). Orexin/hypocretin modulation of the basal 
forebrain cholinergic system: Insights from in vivo microdialysis studies. 
Pharmacology, Biochemistry and Behavior, 90, 156-162
Fadel, J., Pasumarthi, R., & Reznikov, L.R. (2005). Stimulation of cortical 
acetylcholine release by orexin A. Neuroscience, 130, 541-546.
Fujiki, N., Yoshida, Y., Ripley, B., Honda, K., Mignot, E., & Nishino, S. (2001). 
Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and 
in response to food deprivation. Neuroreport, 12, 993-997.
Hagan, J.J., Leslie, R.A., Patel, S., Evans, M.L., Wattam, T.A., Holmes, S.,
Benham, C.D., Taylor, S.G., Routledge, C., Hemmati, P., Munton, R.P., 
Ashmeade, T.E., Shah, A.S., Hatcher, J.P., Hatcher, P.D., Jones, D.N., 
Smith, M.I., Piper, D.C., Hunter, A.J., Porter, R.A., & Upton, N. (1999). 
Orexin A activates locus coeruleus cell firing and increases arousal in the 
rat. The Proceedings o f  the National Academy o f  Sciences (US), 96, 
10911-10916.
Holley, L.A., Turchi, J., Apple, C., & Sarter, M. (1995). Dissociation between the 
attentional effects of infusions of a benzodiazepine receptor agonist and an 
inverse agonist into the basal forebrain. Psychopharmacology, 120, 99- 
108.
Holley, L.A., Wiley, R.G., Lappi, D.A., Sarter, M. (1994). Cortical cholinergic 
deafferentation following the intracortical infusion of 192 IgG-saporin: A 
quantitative histochemical study. Brain Research, 663, 277-286.
Horvath, T. L., Diano, S. & Van den Pol, A. N. (1999). Synaptic interaction
between hypocretin (orexin) and neuropeptide Y cells in the rodent and 
primate hypothalamus: A novel circuit implicated in metabolic and 
endocrine regulations. Journal o f  Neuroscience, 19, 1072-1087.
Iqbal, J., Pompolo, S., Sakurai, T. & Clarke, I. J. (2001). Evidence that orexin- 
containing neurones provide direct input to gonadotropin-releasing 
hormone neurones in the ovine hypothalamus. Journal o f  
Neuroendocrinology, IB, 1033-1041.
Julien, R.M. (2005). A primer o f  drug action. New York: Worth Publishers.
Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong,
P.J., Nishino, S., Mignot, E. (1999). The sleep disorder canine narcolepsy 
is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 
98, 365-376.
McGaughy, J., Dailey, J.W., Morrison, C.H., Everitt, B.J., & Robbins, T.W. 
(2002). Selective behavioral and neurochemical effects of cholinergic 
lesions produced by intrabasalis infusions of 192 IgG-saporin on 
attentional performance in a five-choice serial reaction time task. Journal 
o f Neuroscience, 22, 1905-1913.
McGaughy, J., Everitt, B.J., Robbins, T.W., & Sarter, M. (2000). The role of 
cortical cholinergic afferent projections in cognition: Impact of new 
selective immunotoxins. Behavioural Brain Research, 115, 251-263.
McGaughy, J., Kaiser, T., & Sarter, M. (1996). Behavioral vigilance following 
infusions of 192 IgG-saporin into the basal forebrain: Selectivity on the
35
behavioral impairment and relation to cortical AChE-positive fiber 
density. Behavioral Neuroscience, 110, 247-265.
McGaughy, J. & Sarter, M. (1995). Behavioral vigilance in rats: Task validation 
and effects of age, amphetamine, and benzodiazepine receptor ligands. 
Psychopharmacology, 117, 340-357.
McGaughy, J. & Sarter, M. (1998). Sustained attention performance in rats with 
intracortical infusions of 192 IgG-saporin induced cortical cholinergic 
deaffrentation: Effects of physostigmine and FG 7142. Behavioral 
Neuroscience, 112, 1519-1525.
Mignot, E., Taheri, S., & Nishino, S. (2002). Sleeping with the hypothalamus: 
Emerging therapeutic targets for sleep disorders. Nature Neuroscience 
Supplement, 5, 1071-1075.
Mikkelsen, J.D., Hauser, F., deLecea, L., Sutcliffe, J.G., Kilduff, T.S., Calgari, C., 
Pevet, P., & Simonneaux, V. (2001). Hypocretin (orexin) in the rat pineal 
gland: A central transmitter with effects on noradrenaline induced release 
of melatonin. European Journal o f  Neuroscience, 14, 419—425.
Mileykovskiy, B.Y., Kiyashchenko, L.I., & Siegel, J.M. (2005). Behavioral
correlates of activity in identified hypocretin/orexin neurons. Neuron, 46, 
787-798.
Mondal, M.S., Nakazato, M., Date, Y., Murakami, N., Yanagisawa, M., &
Matsukura, S. (1999). Widespread distribution of orexin in rat brain and 
its regulation upon fasting. Biochemical and Biophysical Research 
Communications, 256, 495—499.
National Institute of Neurological Disorders and Stroke (2008). NINDS
Narcolepsy Information Page, <http://www.ninds.nih.gov/disorders/ 
narcolepsy/narcolepsy.htm.> Retrieved July 1, 2008.
Nelson, C.L., Sarter, M., & Bruno, J.P. (2005). Prefrontal cortical modulation of 
acetylcholine: Release in the posterior parietal cortex. Neuroscience, 32, 
347-359.
Nishino, S., Ripley, B., Overeem, S., Lammers, J. G. & Mignot, E. (2000).
Hypocretin (orexin) deficiency in human narcolepsy. Lancet, 355, 39-40.
Paus, T., Zatorre, R.J., Hofle, N., Caramanos, Z., Gotman, J., Petrides, M., & 
Evan, A.C. (1997). Time-related changes in neural systems underlying 
attention and arousal during the performance of an auditory vigilance task. 
The Journal o f  Cognitive Neuroscience, 9, 392-408.
Posner, M.I. & Petersen, S.E. (1990). The attention system of the human brain. 
Annual Review o f  Neuroscience, 13, 25-42.
Randeva, H. S., Karteris, E., Grammatopoulos, D. & Hillhouse, E. W. (2001). 
Expression of orexin-A and functional orexin type 2 receptors in the 
human adult adrenals, implications for adrenal function and energy 
homeostasis. Journal o f  Clinical Endocrinology and Metabolism, 86, 
4808-4813.
Ripley, B., Overeem, S., Fujiki, N., Nevsimalova, S. Uchino, M., Yesavage, J., Di 
Monte, D., Dohi, K., Melberg, A., Lammers, G.J., Nishida, Y., Roelandse, 
F.W., Hungs, M., Mignot, E., & Nishino, S. (2001). CSF
37
hypocretin/orexin levels in narcolepsy and other neurological conditions. 
Neurology, 57, 2253-2258.
Robbins, T.W. (2002). The 5-choice serial reaction time task: Behavioural
pharmacology and functional neurochemistry. Psychopharmacology, 163, 
362-380.
Robbins, T.W., Everitt, B.J., Marston, H.M., Wilkinson, J., Jones, G.H.., Page, 
K.J. (1989). Comparative effects of ibotenic acid- and quisqualic acid- 
induced lesions of the substantia innominata on attentional function in the 
rat: Further implications for the role of the cholinergic neurons of the 
nucleus basalis in cognitive processes. Behavioural Brain Research, 35, 
221-240.
Rodgers, R.J., Halford, J.C.G, Nunes de Souza, R.L., Canto de Souza, A.L., Piper, 
D.C., Arch, J.R.S., Upton, N., Porter, R.A., Johns, A., & Blundel, J.E. 
(2001). SB-334867, a selective orexin-1 receptor antagonist, enhances 
behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. 
European Journal o f  Neuroscience, 13, 1444-1452.
Sakurai, T. (2007). The neural circuit of orexin (hypocretin): Maintaining sleep 
and wakefulness. Nature Reviews: Neuroscience, 8, 171-181.
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., 
Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., 
Buckingham, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., 
Liu, W.S., Terrett, J.A., Elshourbagy, N.A., Bergsma, D.J., &
Yanagisawa, M.(1998). Orexins and orexin receptors: A family of
38
hypothalamic neuropeptides and G protein-coupled receptors that regulate 
feeding behavior. Cell, 92, 573-85.
Samson, W.K. & Taylor, M.M. (2001). Hypocretin/orexin suppresses corticotroph 
responsiveness in vitro. American Journal o f  Physiology -  Regulatory, 
Integrative, and Comparative Physiology, 281, 1140-1145.
Saper, C.B., Chou, T.C., & Scammell, T.E. (2001). The sleep switch:
Hypothalamic control of sleep and wakefulness. Trends in Neuroscience, 
24, 726-731.
Sarter, M., Givens, B., & Bruno, J.P. (2001). The cognitive neuroscience of
sustained attention: Where top-down meets bottom-up. Brain Research 
Reviews, 35, 146-160.
Sarter, M., Hasselmo, M.E., Bruno, J.P., & Givens, B. (2005). Unraveling the
attentional functions of cortical cholinergic inputs: Interactions between 
signal-driven and cognitive modulation of signal detection. Brain 
Research Reviews, 48, 98-111.
Sartin, J.L., Dyer, C., Matteri, R., Buxton, D., Buonomo, F., Shores, M., Baker, J., 
Osborne, J.A., Braden, T., & Steele, B. (2001). Effect of 
intracerebroventricular orexin-B on food intake in sheep. Journal o f  
Animal Science, 19, 1573-1577.
Sutcliffe, J.G. & de Lecea, L. (2002). The hypocretins: Setting the arousal 
threshold. Nature Reviews, 3, 339-349.
Thakkar, M.M., Ramesh, V., Strecker, R.E., & McCarley, R.W. (2001).
Microdialysis perfusion of orexin-A in the basal forebrain increases
39
wakefulness in freely behaving rats. The Italian Archives o f Biology, 139, 
313-328.
Turchi, J., & Sarter, M. (2001). Bidirectional modulation of basal forebrain N-
methyl-D-aspartate receptor function differentially affects visual attention 
but not visual discrimination performance. Neuroscience, 104, 407-417.
Verhaeghen, P. & Cerella, J. (2002). Aging, executive control, and attention: A 
review of meta-analyses. Neuroscience and Biobehavioral Reviews, 26, 
849-857.
Waite, J.J., Chen, A.D., Wardlow, M.L., Wiley, R.G., Lappi, D.A. & Thai, L.J. 
(1995). 192 immunoglobulin G-saporin produces grades behavioral and 
biochemical changes accompanying the loss of cholinergic neurons in the 
basal forebrain and cerebellar purkinje cells. Neuroscience, 65, 463-476.
Werner, J. & Bienek, A. (1990). Loss and restoration of preoptic
thermoreactiveness after lesions of the rostral raphe nuclei. Experimental 
Brain Research, 80, 429-435.
Wurtz, R.H. & Goldber, M.E. (1972). The primate superior colliculus and the 
shift of visual attention. Investigative Ophthalmology, 11, 441-50.
Yamamoto, Y., Ueta, Y., Date, Y., Nakazato, M., Hara, Y., Serino, R., Nomura, 
M., Shibuya, I., Matsukura, S., & Yamashita H. (1999). Down regulation 
of the prepro-orexin gene expression in genetically obese mice. Molecular 
Brain Research, 65, 14-22.
Yamanaka, A., Sakurai, T., Katsumoto, T., Yanagisawa, M. &Goto, K. Chronic 
intracerebroventricular administration of orexin-A to rats increases food
40
intake in daytime, but has no effect on body weight. Brain Research, 849, 
248-252.
Yoshida, Y., Fujiki, N., Nakajima, T., Ripley, B., Matsumura, H., Yoneda, H.,
Mignot, E., & Nishino, S. Fluctuation of extracellular hypocretin-1 (orexin 
A) levels in the rat in relation to the light-dark cycle and sleep-wake 
activities. European Journal o f  Neuroscience, 14, 1075-1081.
Zaborszky, L., Gaykema, R.P., Swanson, D.J., & Cullinan, W.E. (1997). Cortical 
input to the basal forebrain. Neuroscience, 79, 1051-1078.
41
Figure Caption
Figure 1. Correct detection of the 500 ms signal was decreased following the 
highest dose (5.0 mg/kg SB-334867) as compared to vehicle administration. 
Figure 2. Correct detection of the 25 ms signal was increased following the 1.0 
mg/kg dose of SB-334867 as compared to vehicle administration.
Figure 3. The percentage of correct rejections was not significantly affected by 
administration of SB.334867.
Figure 4. Overall, correction detection of signals was not affected by dose.
Figure 5. A decrease in signal detection at the 500 ms signal duration was present 
following the 0.6 pg/pl infusion of SB-334867. This effect was not significant (p 
> 0.05).
Figure 6. The percentage of correct rejections was increased during the second 
block of trials as compared to the first and second block of trials. This effect was 
not affected by SB-334867 dose. * Indicatesp  < 0.01.
Figure 7. The overall percentage of correct rejections was not significantly 
affected by intrabasalis infusions of SB-334867.
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